Please login to the form below

Not currently logged in
Email:
Password:

Bayer shares rise on Novartis takeover rumour

Shares in German pharmaceutical company Bayer have risen on renewed market rumour that Swiss-headquartered Novartis may be considering acquiring the company.

Shares in German pharmaceutical company Bayer have risen on renewed market rumour that Swiss-headquartered Novartis may be considering acquiring the company.

On 15 August 2007, rumours that Novartis might offer EUR 70 per share saw Bayer's stock rise by up to seven per cent.

Bayer has neither confirmed nor denied the takeover, while Novartis has also remained silent on the matter.

Bayer shares rose 3.2 per cent to rest at EUR 56.41 in morning trading on 22 August, while Novartis' shares were slightly lower.

Dresdner Kleinwort analysts have been skeptical that Novartis, which has a market capitalisation of USD 143bn, would make a play for Bayer, which is valued at USD 54bn at the current share price.

Another reason to disbelieve the rumour is that Bayer recently expanded its healthcare business with the 2006 EUR 17bn acquisition of Schering.

22nd August 2007

Share

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Onyx Health

Onyx Health is a healthcare communications and PR agency based in the North East of England, but with a national...

Latest intelligence

Biosimilars and beyond: innovating for improved patient outcomes
How Europe’s biosimilar landscape has rapidly evolved over the last two decades, bringing biological medicines to more patients than ever before...
World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
Great Expectations – exploring the counterpoint between advances in oncology and the challenges of ensuring life-changing medicines reach patients...
Strategic behaviour
Strong strategising depends on your colleagues’ behaviour...